n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, February 26th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Digatrade Financial Corp. (DIGAF)

MarketWatch and InvestorsHub reported earlier on Digatrade Financial Corp. (DIGAF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Digatrade Financial Corp. is an international digital asset exchange and blockchain development services company. It engages in the licensing, development, and branding of a digital exchange trading platform and a peer to peer electronic payment processing network for enabling users to trade fiat and alternative currencies. In essence, DIGATRADE is a Digital Asset, Currency (Bitcoin) Exchange, and Internet Financial Services Company owned and operated by Digatrade Financial Corp.

Established in 2000, the Company lists on the OTC Markets’ OTCQB. It formerly went by the name Bit-X Financial Corporation. It changed its corporate name to Digatrade Financial Corp. in October 2015. Digatrade Financial has its head office in Vancouver, British Columbia.

Currently, Digatrade Financial is developing several new technologies for the Digatrade Core 2.0 Digital Asset Trading Platform. In addition, the Company is seeking more new opportunities and partners for growth as Bitcoin (BTC) continues to increase in value with a market capitalization now in excess of $23.5 Billion.

Digatrade has launched the Digatrade OTC Trade Desk. The new Digatrade Over-the-Counter (OTC) trading service will let KYC verified customers to complete trades outside the online liquidity order book at competitive market prices.

Digatrade Financial provides operational support specializing in web-based digital currency exchange and transaction services for the cryptographic digital currencies. This includes Bitcoin and other alternative digital coins.

The Company provides a user-friendly, secure, and affordable platform to buy and sell Bitcoin and other digital assets. Digatrade provides a 24-hour online platform. This platform provides the automated matching of orders between its registered members.

The proprietary Digatrade trading and matching engine manages high volume, high throughput, and low latency trading. Also, this engine features blended multi-currency settlement in addition to real time FX pricing and risk management fully powered by ANX Technologies. The order engine delivers pre-scan indicative pricing. Users can decide to either fix the quantity of Bitcoins or fix the price paid for every order.

This month, Digatrade Financial announced the listing addition of Ethereum ''ETH'' paired to BTC on the trading platform. This will afford Digatrade customers and shareholders first access to register for the Digafund21 (D21) token release on the already established, safe, and secure Digatrade platform. At present, the Company is now evaluating security protocol to increase crypto-currency pairings, which may include DASH, EOS, BITCOIN CASH, TETHER, MONERO, MERCURY, ZCASH, and NEO, among others.

Digatrade Financial Corp. (DIGAF), closed Monday's trading session at $0.15, up 11.03%, on 2,133,932 volume with 228 trades. The average volume for the last 60 days is 1,032,607 and the stock's 52-week low/high is $0.04/$1.06.

Avalon Globocare Corp. (AVCO)

OTC Markets, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon’s management draws on their abundance of experience and extensive networks in the biotechnology industry, health care management, as well as academia. Avalon Globocare is based in Freehold, New Jersey. The Company lists on the OTC Markets’ OTCQB.

Avalon Globocare is a premier healthcare management provider and biotechnology developer. Avalon’s commitment is to integrating and managing worldwide healthcare resources. In addition, Avalon, by way of its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities.

The Company’s “Avalon Cell” platform concentrates on cell-based therapies and technologies. Its focus is in the field of in vitro diagnostics, regenerative medicine, and also cancer immunotherapy. Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization internationally.

The “Avalon Rehabilitation” platform is a turnkey, complete suite of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. Regarding Avalon Globocare’s healthcare facility, it presently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

Last week, Avalon Globocare announced that its majority-owned subsidiary, GenExosome Technologies, Inc., acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. At the same time, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, whereby GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

This week, Avalon Globocare announced that it appointed former Congressman, Mr. Billy Tauzin, to the Company’s Board of Directors. Congressman Tauzin has a long and distinguished 36-year elective career. It culminated in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives. The ECC supervises food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.

Avalon Globocare Corp. (AVCO), closed Monday's trading session at $1.40, up 5.18%, on 11,500 volume with 10 trades. The average volume for the last 60 days is 11,461 and the stock's 52-week low/high is $0.51/$4.60.

CurAegis Technologies, Inc. (CRGS)

OTC Markets and InvestorsHub reported on CurAegis Technologies, Inc. (CRGS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions - its CURA Division and its Aegis Division. CurAegis is presently focusing on commercialization strategies in varied technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. CurAegis Technologies is headquartered in Rochester, New York.

The CURA System consists of hardware and software that measures manifold metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the decrease in a person’s alertness and to train persons on how to improve alertness levels.

The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. CurAegis Technologies completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company earlier said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, was designed for aviation professionals. If the CURA (Circadian User Risk Assessment) software detects an issue, Z-Coach creates a back-end solution required to induce change and improve behavior. The program is broken down into two parts: Z-Coach Education and Z-Coach Intervention.

Moreover, the Company’s Aegis hydraulic pump (Aegis Division) is a unique hydraulic design. Its objective is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.

Concerning the Aegis Division’s Aegis Pump and Motor, it has eliminated the rotating piston group (the cylinders are stationary). This makes the pump very strong and easy to manufacture. The Company’s patented valving has been integrated to increase efficiencies at peak and off peak operation.

The Company’s plan is to license its technology to major manufacturers. It may consider an exclusive licensing agreement for a period of time if it believes that it is the best way to reach the original equipment manufacturer (OEM) and after-market customers.

Concerning the CURA System, it now works with iOS and Android phones. The Company has aligned the communications between its watch, the smart phone and its cloud.

The CURA System will make an individual aware of the importance of sleep in their daily life. It will show one how to easily change their behavior to make their life safer, healthier, and longer. In addition, it gives a person accurate and relevant real-time information about their current and long-term sleep and fatigue health.

CurAegis Technologies, Inc. (CRGS), closed Monday's trading session at $0.34, up 9.68%, on 28,500 volume with 5 trades. The average volume for the last 60 days is 16,735 and the stock's 52-week low/high is $0.246/$1.49.

Assure Holdings Corp. (ARHH)

Streetwise Reports, OTC Markets, Stockhouse, and Barchart reported on Assure Holdings Corp. (ARHH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Assure Holdings Corp. works with neurosurgeons and orthopedic spine surgeons to provide a turnkey group of services that support intraoperative neuro-monitoring activities during invasive surgeries. The Company centers chiefly on supporting spinal surgeries. Nonetheless, it has plans in place to support other classes of medicine that rely on the standard of care that intraoperative neuro-monitoring provides.

Assure Holdings, together with its subsidiaries, delivers technical and professional surgical support services in association with intraoperative neuro-monitoring procedures (IONM). Assure Holdings has its corporate office in Parker, Colorado. The Company’s shares trade on the OTC Markets’ OTCQB.

Intraoperative Neurophysiological Monitoring (IONM) is used to monitor patients’ unique neural functions associated with the brain, spinal cord, and peripheral nerves. Assure has a highly skilled staff that can cover cases ranging from spinal cord monitoring to complicated intracranial brain function mapping.

The goal of IONM is to identify changes in brain, spinal cord, and/or peripheral nerve function. This is to prevent complications that could result in irreversible nerve damage.

Assure employs its own staff of technologists. In addition, the Company utilizes its own state-of-the-art monitoring equipment. Assure handles 100 percent of intraoperative neuromonitoring scheduling and setup, and bills for the provision of all technical services.

When a person is undergoing a delicate procedure that involves working near critical nervous structures, Assure will provide state-of-the-art guidance and real time information. This is to assist with a positive outcome.

Additionally, Assure employs the highest quality technologists in the industry. Assure technologists are in the operating room. They monitor the procedures in real time.

Monitoring procedures include Neurological Surgery – aneurysms, brain tumors, cervical fusion, lumbar fusion, peripheral nerve exploration, and resection of spinal cord tumors. Monitoring procedures also include Otolaryngology Surgery – acoustic neuroma, parotidectomy, and tympanomastoidectomy.

Moreover, monitoring procedures include Orthopedic Surgery – acetabular fractures, cervical fusion, lumbar fusion, scoliosis correction, spinal deformity, thoracic fusion, total hip replacement and revision, and shoulder replacements.

Recently, Assure Holdings announced that it performed its first neuromonitoring case in Louisiana. The new partner, Culicchia Neurological Clinic, consists of four surgeons. They specialize in spine, neuro otology and cranial surgeries. Louisiana represents the third State where surgeons have chosen to use the Assure platform.

Procedures are administered at three locations across the State. They involve a broad assortment of disorders. Collectively, the Culicchia group performed more than 1,000 surgeries last year.

Assure Holdings Corp. (ARHH), closed Monday's trading session at $3.158, up 2.38%, on 3,400 volume with 5 trades. The average volume for the last 60 days is 6,449 and the stock's 52-week low/high is $1.00/$3.50.

H/Cell Energy Corporation (HCCC)

MarketWatch, OTC Markets, Marketbeat, Stockopedia, 4-Traders, Wall Street Analyzer, Trading View, Oil & Gas 360, and Market Exclusive reported on H/Cell Energy Corporation (HCCC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation is a systems integrator headquartered in Flemington, New Jersey. The Company centers on the design and implementation of clean energy solutions. These include solar, battery technology, and hydrogen energy systems. The Company serves the residential, commercial, and government sectors. H/Cell Energy’s shares trade on the OTC Markets Group’s OTCQB.

Furthermore, by way of its Pride Group subsidiary, H/Cell Energy provides security systems integration. The Pride Group is headquartered in Australia.

H/Cell Energy manages all projects. The Company has developed and implemented a hydrogen energy system utilized to totally power a residence or commercial property with clean energy. This is so the property can run independent of the utility grid as well as provide energy to the utility grid for monetary credits. The innovative system utilizes renewable energy as its source for hydrogen production.

H/Cell Energy named the hydrogen energy system the HC-1. This is a system consisting of solar panels, inverters, batteries, a hydrogen generator, a fuel cell and a hydrogen storage tank.

The design of each HC-1 system is to accommodate the electrical loads for an end user. The HC-1 system is scalable. It can be configured to meet any kilowatt hour (kWh) demands.

The Company has two completed projects to date. One is the De Tiberge Property, in Pennington, New Jersey. The other is the Strizki Property in Hopewell, New Jersey, which was the first hydrogen energy system installed in North America.

Earlier this month, H/Cell Energy announced that effective February 1, 2018, the Company acquired PVBJ, Inc. of Downingtown, Pennsylvania for $1 million of H/Cell Energy stock and $221,800 in cash. PVBJ is well recognized for the design, installation, maintenance and emergency service of environmental systems in commercial and residential markets.

Moreover, PVBJ is currently expanding into renewable energy systems. Mr. Paul Benis, PVBJ’s President, will remain in his position and became an Executive Vice President of H/Cell Energy.

Mr. Andrew Hidalgo, Chief Executive Officer of H/Cell Energy, said, “Our acquisition strategy focuses on companies that are profitable, have a significant customer base that can be introduced to our technology and have a talented group of technicians that can be trained to install our systems. PVBJ meets all these requirements. They have been a very successful company and we look forward to assimilating their organization into HCCC.”

H/Cell Energy Corporation (HCCC), closed Monday's trading session at $3.00, up 9.09%, on 300 volume with 3 trades. The average volume for the last 60 days is 861 and the stock's 52-week low/high is $1.00/$4.00.

Largo Resources Ltd. (LGORF)

InvestorsHub, Stockhouse, MarketWatch, OTC Markets, InvestorIntel, Capital Cube, Investors Hangout, Junior Mining Network, UptickNewswire, Equities, Barchart, The Northern Miner, Proactive Investors, MetalsNews, and Marketbeat reported on Largo Resources Ltd. (LGORF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Largo Resources Ltd. is a strategic mineral company based in Toronto, Ontario. The Company concentrates on the production of vanadium pentoxide at its Vanadio de Maracás Menchen Mine. Largo Resources started production at the Maracás Menchen Mine in August of 2014. At present, the Company is ramping-up production.

Incorporated in 1988, Largo Resources lists on the OTC Markets Group’s OTCQB. The company was previously known as Consolidated Kaitone Holdings Ltd. It changed its name to Largo Resources Ltd. in June of 2004.

The Company mainly explores for vanadium, iron, tungsten, molybdenum, chromite, palladium, and platinum group metals (PGMs). Vanadium is chiefly used as an alloy to strengthen steel and lessen its weight. Vanadium enhanced steels are used in rebar, automobiles, transport infrastructure, and more.

In addition, Largo Resources has interests in a portfolio of other projects. These include a 100 percent interest in the Currais Novos Tungsten Tailings Project in Brazil, and a 100 percent interest in the Campo Alegre de Lourdes Iron-Vanadium Project in Brazil. The Company also has a 100 percent interest in the Northern Dancer Tungsten-Molybdenum property in the Yukon Territory.

In January, Largo Resources announced that it set a new monthly production record at its Maracás Menchen Mine during the month of December 2017. Largo produced 903 tonnes of vanadium pentoxide (vanadium or V2O5) in December. This exceeded by 15 tonnes its previous monthly production record of 888 tonnes set in August of 2017.

The production in December 2017 was 12.9 percent above the plant's nameplate capacity. Largo said that the production is the result of its operating team's efforts to enhance efficiencies and to continually improve production.

Because of strong production throughout Q4 2017, Largo Resources also achieved a new quarterly production record at its Maracás Menchen Mine during Q4 2017. It produced 2,539 tonnes of V2O5 in Q4 2017. This exceeded by 26 tonnes its previous quarterly production record of 2,513 tonnes set in Q3 2017. The production in Q4 2017 was 5.8 percent above the plant's nameplate capacity.

Earlier this month, Largo Resources announced its support for the new rebar standard announced on February 9, 2018 by the Standardization Administration for the People's Republic of China (PRC). The announcement includes a special action to reduce the use of all substandard steels in the PRC. The expectation is that the new rebar standard and related action will be implemented by November 2018. China produces about 200 million metric tons of rebar annually.

Largo Resources Ltd. (LGORF), closed Monday's trading session at $0.987, down 1.10%, on 41,905 volume with 12 trades. The average volume for the last 60 days is 52,531 and the stock's 52-week low/high is $0.2616/$1.154.

MetaStat, Inc. (MTST)

Goldman Small Cap Research, Innovative Marketing, Club Penny Stocks Network, OTCBB Journal, First Penny Picks, StocksImpossible, Pumps and Dumps, and The MicrocapNews reported previously on MetaStat, Inc. (MTST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, MetaStat, Inc. is a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients. The Company develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis - the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat’s focus is on breast, prostate, lung, and colorectal cancers, where systemic metastasis is responsible for approximately 90 percent of all deaths.

A life sciences company, MetaStat is headquartered in Boston, Massachusetts. In essence, MetaStat’s core expertise includes an understanding of the mechanisms and pathways that drive tumor cell invasion and metastasis, and also drug resistance to certain targeted therapies and cytotoxic chemotherapies.

The basis of MetaStat’s function-based diagnostic platform technology is on the identification and understanding of the vital role of the mena protein and its isoforms (a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors).

The design of the MetaSite Breast™ and MenaCalc™ product lines are to accurately stratify patients based on their individual risk of metastasis and to enable clinicians to better customize cancer treatment decisions through positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the damaging side effects and cost of chemotherapy.

The MetaSite Breast™ test measures the process of systemic metastasis. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is widely applicable in solid epithelial-based cancers.

The intention of the MetaSite Breast™ test is for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive (1-3), estrogen receptor-positive, HER2-negative disease.

In August of 2017, MetaStat announced that accomplished drug developer, Renato T. Skerlj, Ph.D., joined the Company as a member of its Scientific and Clinical Advisory Board. Dr. Skerlj has more than 25 years of pharmaceutical experience in drug development resulting in two marketed drugs: Invanz® and Mozobil® and numerous drugs in clinical development.

He serves as Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a Co-Founder and a Member of the Scientific Advisory Board of X4 Pharmaceuticals, Inc. He is also Co-Founder of Noliva Therapeutics.

MetaStat, Inc. (MTST), closed Monday's trading session at $1.13875, down 0.98%, on 6,000 volume with 3 trades. The average volume for the last 60 days is 5,817 and the stock's 52-week low/high is $0.55/$1.61.

Pharma-Bio Serv, Inc. (PBSV)

Zacks reported earlier on Pharma-Bio Serv, Inc. (PBSV), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. Its main business is Food and Drug Administration (FDA) and other global regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico.

Pharma-Bio Serv has its corporate office in Dorado, Puerto Rico. In addition, the Company has operations in the United States Ireland, and Spain. Pharma-Bio Serv lists on the OTC Markets Group’s OTCQB.

The Company supports its clients through the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Moreover, this includes Quality Systems; Technology Transfer; Validation, and also Manufacturing Controls & Process Support.

Pharma-Bio Serv’s services also include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

The Company’s divisions include Scienza Labs, the abovementioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

Recently, Pharma-Bio Serv announced that Net Revenues for the year ended October 31, 2017 were $15.6 million. This represents a decrease of roughly $4 million, or 20 percent, versus last year.

The revenue decrease is primarily because of decreases in the Puerto Rico consulting market and the Puerto Rico Lab of $3.7 and $0.4 million, respectively. In addition, these results include declines of $0.2 and $0.1 million, in the Puerto Rico consulting market and the Puerto Rico Lab respectively, which are due to the impacts of Hurricanes Irma and Maria, and declines in the U.S. and Brazil consulting markets of $0.2 and $0.1 million, respectively.

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "As of the end of fiscal year 2017, we have quickly recovered from the Hurricanes, focused our attention back to our strategies, including the US consulting services strategy, with a more streamlined business development approach, and started benefiting from incoming consulting opportunities in Europe."

Pharma-Bio Serv, Inc. (PBSV), closed Monday's trading session at $0.52, even for the day, on 5,000 volume with 4 trades. The average volume for the last 60 days is 7,419 and the stock's 52-week low/high is $0.325/$0.83.

Pacific Green Technologies, Inc. (PGTK)

Value Penny Stocks, WINNINGOTC, TryBestPennyStocks.biz, Wall Street Mover, Journal Transcript, InvestorSoup, SuperStockTips, Stock Preacher, Equity Observer, Jet-Life Penny Stocks, SMS Penny Picks, Beacon Equity Research, eliteotc, Penny Stocks Finder, Penny Stock Craze, SmallCapAllStars, The Street, and Wall Street Beauties reported on Pacific Green Technologies, Inc. (PGTK), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Pacific Green Technologies, Inc. focuses on addressing the world’s need for cleaner and more sustainable energy. The Company’s strategy is to build, through organic development and acquisition, a portfolio of patented competitive progressive technologies designed to meet increasingly stringent environmental standards. Pacific Green Technologies China Limited (PGTC) is a subsidiary of Pacific Green Technologies, Inc. Pacific Green Technologies is based in San Jose, California.

Pacific Green Technologies China Limited (PGTC) has a Commercial Joint Venture Agreement (JV) with POWERCHINA SPEM Co., Limited. The JV Agreement sets out the terms for PGTC and POWERCHINA SPEM to co-operate exclusively in China for 10 years to develop the ENVI-Clean™ and ENVI-Pure™ emission control system to become the market leader in the Coal Fired Power, Steel Works, Cement Works, as well as Waste to Energy industry sectors.

Pacific Green Technologies has its Envi-Marine™ system. This is a seawater scrubber. Envi-Marine™ takes an alternative approach to seawater scrubbing through using the Envi-Clean™ inventive turbulent scrubbing head to provide interactive contact between the seawater and the exhaust gas in a turbulent zone containing a high amount of surface area for gas/liquid absorption.

Pacific Green’s ENVI-Clean™ is a patented Emissions Control System. The design of it is to remove pollutants from flue gases. ENVI-Clean™ is suitable for the removal of acid gases and particulate matter from high volume processes.

In addition, the ENVI-Pure™ system is a refined version of the ENVI-Clean™ system, designed to remove a wider variety of contaminants with very high efficiency as required by Waste to Energy (WtE) and Biomass power plants.

Pacific Green Technologies earlier signed a Memorandum of Understanding (MOU) with POWERCHINA SPEM Co., Limited to incorporate a new company. Pacific Green will own 50.1 percent and POWERCHINA SPEM 49.9 percent.

Initially, the jointly owned company will market Pacific Green's patented ENVI-Systems™ Technology for removal of noxious gases. It will then look to acquire licenses for more complementary technologies to market in China and Southeast Asia.

Earlier this month, Pacific Green Technologies announced that its subsidiary Pacific Green Technologies Marine Limited signed a brokerage agreement with Poten & Partners to assist Pacific Green Technologies in marketing its marine industry leading ENVI-Marine™ Exhaust Gas Scrubbing System. Poten & Partners provides ship and commodity brokerage, consulting, business intelligence and commercial advisory services to its clients.

Installing Exhaust Gas Scrubbing Systems permits ship owners and charterers to continue using low cost "bunker fuel". This is rather than having to switch to high-cost low sulphur gas oil for the life of the ship, while meeting the imminent IMO legislation in 2020 for ships to considerably reduce their emissions.

Pacific Green Technologies, Inc. (PGTK), closed Monday's trading session at $1.35, even for the day, on 2,800 volume with 9 trades. The average volume for the last 60 days is 8,280 and the stock's 52-week low/high is $0.25/$1.40.

Vitality Biopharma, Inc. (VBIO)

SmallCap Network, Stock Beast, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s dedication is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, the Company has developed a unique capability to produce molecules through glycosylation, a form of enzymatic biosynthesis that was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products. Vitality Biopharma has its corporate headquarters in Los Angeles, California.

Late in 2015, the Company successfully modified cannabidiol (CBD), which is not psychoactive, and in continuing work has created a novel class of pharmaceuticals named cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while reducing or avoiding the systemic delivery of THC into the bloodstream.

Vitality Biopharma completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. It has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be reduced or eliminated.

The Company can biosynthesize cannabinoid glycosides (cannabosides) by way of enzyme biosynthesis. Vitality Bippharma is one of only a very few groups around the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides).

The Company has obtained positive results demonstrating antimicrobial activity of cannabinoids. It filed for patent protection on the use of cannabinoid compounds for the treatment of microbes. This includes Clostridium difficile and other "superbug" pathogens.

Vitality Biopharma announced in October 2017 the achievement of a biosynthesis breakthrough. It has developed a proprietary biosynthesis technology that can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds named cannabinoid glycosides, or cannabosides.

Vitality Biopharma has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. The Company is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. Its plan is to complete a first-in-man clinical study in the first half of this year.

The treatment indications Vitality Biopharma plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain).

Mr. Robert Brooke, Chief Executive Officer and Co-Founder of Vitality Biopharma, said, “As independent clinical studies are demonstrating the therapeutic effects of THC, we are well positioned with our VITA-100 gut-restricted prodrug formulation.

Vitality Biopharma submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). With approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease.

Vitality Biopharma, Inc. (VBIO), closed Monday's trading session at $2.00, up 0.50%, on 133,365 volume with 257 trades. The average volume for the last 60 days is 171,484 and the stock's 52-week low/high is $1.30/$2.75.

graphic

The QualityStocks
Company Corner

graphic
graphic

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0044, up 120.00%, on 17,648,171 volume with 187 trades. The stock’s average daily volume over the past 60 days is 251,682, and its 52-week low/high is $0.0005/$0.008.

Consorteum Holdings, Inc. (OTCPK:CSRH), a software development company and mobile device solutions provider, today announced that its wholly owned subsidiary, 359 Mobile Inc. (“359”), has  entered into a Joint Business Agreement  with DevLex Ltd. The agreement creates an exclusive alliance for the integration of the DevLex Predictive Analytics Platform (“DV-PA”) with 359’s Universal Mobile Interface™ (“UMI”).

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company's commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ ("UMI") solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company's UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum's wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company's UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI's technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum's primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum's management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum's management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings, Inc. Announces Joint Business Agreement with DevLex Ltd.

NetworkNewsBreaks – Consorteum Holdings, Inc. (CSRH) Extends Agreement, Combines Strengths with Knockout Gaming, Inc.

Consorteum Holdings, Inc. (CSRH) Extends Strategic Agreement with Knockout Gaming, Inc.

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.9508, up 9.87%, on 279,233 volume with 225 trades. The stock’s average daily volume over the past 60 days is 292,721, and its 52-week low/high is $0.3148/$1.3041.

NetworkNewsAudio announces the Audio Press Release (APR) titled "Rise of Electric Cars Fuels Cobalt Market Surge," featuring First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF). To hear the NetworkNewsAudio version, visit: http://nnw.fm/1TVaD.To read the original editorial, visit: http://nnw.fm/6VbnF. Also today, NetworkNewsWire issued a report covering how the blossoming EV industry is driving demand for battery grade lithium and cobalt, placing First Cobalt Corp. in an enviable position.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

NetworkNewsAudio Announces Audio Press Release (APR) on First Cobalt Corp. Moves to Meet Growing Demand for Cobalt

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Set to Exploit Monopoly in Battery Grade Cobalt Refining

NetworkNewsWire Announces Publication on Cobalt’s Rising Demand to Power Green Cars

IEG Holdings Corp. (IEGH)

The QualityStocks Daily Newsletter would like to spotlight IEG Holdings Corp. (IEGH). Today, IEG Holdings Corp. closed trading at $0.30, up 9.89%, on 175,833 volume with 45 trades. The stock’s average daily volume over the past 60 days is 92,692 and its 52-week low/high is $0.14/$4.20.

IEG Holdings Corporation (OTCQB: IEGH) announced today that its wholly owned subsidiary, Investment Evolution Crypto LLC, ("IE Crypto") has signed leading blockchain software consultants, Intellectsoft LLC ("Intellectsoft") in Silicon Valley, California, to provide blockchain development services for IEG Holdings' cryptocurrency.

IEG Holdings Corp. (IEGH) is a publicly traded, global leader in consumer finance providing small-sized online personal loans in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand "Mr. Amazing Loans." Based in Las Vegas, the company originates consumer loans in 20 states: Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri, Nevada, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia and Wisconsin via its online platform and distribution network. IEGH is a licensed direct lender with state licenses and/or certificates of authority to lend in each state and offers all loans within the prevailing statutory rates.

Mr. Amazing Loans is a leading FinTech company specializing in dedicated loan amounts of $5,000 to $10,000 offered directly to consumers through an easy-to-use website known for its professional interaction with applicants. All loans are originated, processed and serviced out of the company's Las Vegas corporate offices, eliminating the need for physical locations in each state where IEGH is licensed to conduct business. The company's loans are unsecured consumer loans that mature in five years at interest rates significantly less than those of payday lenders. Consumers are able to receive same-day processing and are assured of no hidden or additional fees, no prepayment penalty, with repayment and interest rates fixed at 29.9% or less Annual Percentage Rate (APR) for the life of the loan.

The Center for Responsible Lending states the typical payday loan has rates ranging from 391% to 521% APR on loans that typically range from $100 to $1,000. Conversely, Mr. Amazing Loans's terms are designed with low fixed repayments to fit into consumer budgets with the added goal of helping clients reach a stronger financial position. Loan funds are deposited directly into an approved consumer's checking account and may be approved the same day after necessary application documentation is received.

IEG Holdings has also incorporated Investment Evolution Crypto, LLC., a 100 percent owned subsidiary, and tasked the new company with exploring business opportunities in the cryptocurrency/blockchain industry. Specifically, the subsidiary company will explore the legalities and economic risks of entering into a joint venture with IEGH's other 100 percent owned subsidiary company, Investment Evolution Corporation dba Mr. Amazing Loans. Among the questions to be answered during this development planning stage are whether Mr. Amazing Loans should accept repayment of customer loans in the form of leading crypto/blockchain currencies such as Bitcoin, provide the equivalent of USD $5,000 and $10,000 loans to consumers in cryptocurrencies, and potentially create and issue an Investment Evolution cryptocurrency.

Paul Mathieson, IEG Holdings' chairman and Chief Executive Officer, has over 19 years of finance industry experience in lending, funds management, stock market research and investment banking. He has been a member of the board of directors at IEGH since 2012 and of its subsidiary since 2009. Mathieson founded IEG Holdings Limited in Sydney, Australia, launching the Amazing Loans business in that country in 2005 and then in the United States via IEGC in 2010. He was awarded Ernst & Young's 2007 Australian Young Entrepreneur of the Year (Eastern Region). Mathieson is joined by Carla Cholewinski, who serves as chief operating officer with over 37 years of experience in the finance industry including banking, credit union management, regulatory oversight, debt securitization and underwriting. Disclaimer

IEG Holdings Corp. Blog

IEG Holdings Corp. News:

IEG Holdings Signs Leading Blockchain Software Consultants, Intellectsoft, for IEG Holdings Cryptocurrency Blockchain Development Services and Reveals New Philippines Cryptocurrency Remittance Plans

NetworkNewsBreaks – IEG Holdings Corp. (IEGH) Aims to Create Exclusive Gold Metal-backed Cryptocurrency

IEG Holdings Corp. (IEGH) Engages NetworkNewsWire for Corporate Communications Solutions

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.36, up 2.86%, on 33,389 volume with 16 trades. The stock’s average daily volume over the past 60 days is 14,073, and its 52-week low/high is $0.01/$0.80.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:PRVCF) (FSE:18H), announces the appointment of Dr. Maher Khaled as the Company’s Director of International Operations.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

PreveCeutical Announces Appointment of Dr. Maher Khaled as Director of International Operations

NetworkNewsAudio Announces Audio Press Release (APR) on PreveCeutical Medical Inc. Transforming Industry with Cannabinoid Delivery Advancements

NetworkNewsWire Announces Publication on Unique New Paradigms in Cannabinoid Drug Delivery

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF)

The QualityStocks Daily Newsletter would like to spotlight Global Hemp Group, Inc. (GBHPF). Today, Global Hemp Group, Inc. closed trading at $0.123, off by 1.60%, on 157,941 volume with 41 trades. The stock’s average daily volume over the past 60 days is 439,249, and its 52-week low/high is $0.0115/$0.316.

It was the passage of the Marihuana Tax Act in 1938, which banned cultivation of cannabis, which changed the fortunes of the industry. Hemp production in the U.S. shrank and has remained in that atrophied state since then. However, recent legislative initiatives are a signal that happier days lie ahead for hemp, and Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is well positioned to benefit.

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Hemp Group, Inc. Company Blog

Global Hemp Group, Inc. News:

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) Pursuing Opportunities in America’s ‘New Billion-Dollar Crop’

CannabisNewsBreaks – Why Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is “One to Watch”

Global Hemp Group Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Aims to be a Leader in the Multi-Faceted Industrial Hemp Market

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.5035, off by 6.93%, on 4,968,596 volume with 1,280 trades. The stock’s average daily volume over the past 60 days is 13,675,964, and its 52-week low/high is $0.0006/$0.957.

PotNetwork Holding Inc. (OTC Pink:POTN) is pleased to announce that its wholly owned subsidiary, Diamond CBD, Inc., which exhibited  its 2018 product line at the 37th CHAMPS Trade Show at the Las Vegas Convention Center on February 19-21, 2018, recorded over $270,000 in sales at the show.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding’s Diamond CBD Books Over $270,000 in Sales at CHAMPS Winter Show at Las Vegas Convention Center

With $756,000 in Sales, PotNetwork Holding, Inc. Continues Strong Upward Trend, Reporting Revenues over 360% Higher Than Corresponding 2017 Timeframe

PotNetwork Holding’s Diamond CBD Showcases Expanded Product Line at CHAMPS Winter Show at Las Vegas Convention Center

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.47, off by 7.55%, on 190,772 volume with 280 trades. The stock’s average daily volume over the past 60 days is 485,320 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. To view the full press release, visit: http://cnw.fm/en9Z5

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0635, off by 9.29%, on 5,150,148 volume with 371 trades. The stock’s average daily volume over the past 60 days is 11,809,445, and its 52-week low/high is $0.0132/$0.415.

On February 14, 2018, SinglePoint, Inc. (OTCQB: SING) released an update for shareholders regarding its recent uplisting to the OTCQB Venture Market (http://cnw.fm/w8eUZ). With a market cap of just over $65 million, the company is currently busy completing its 2017 audit for the imminent reporting of its financial results. Also today, NetworkNewsWire announced the publication of an editorial featuring SinglePoint, Inc. (OTC:SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. To view the full publication, titled “Blockchain Innovations Set to Disrupt Healthcare,” visit: http://nnw.fm/8HkkD.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint, Inc. (SING) Details OTCQB Uplisting, New Board Appointment

NetworkNewsWire Announces Publication on Innovative Blockchain Applications Revolutionizing Healthcare

NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Recent LOI, Acquisition Strategy in Interview on MoneyTV

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.653, off by 10.64%, on 617,847 volume with 607 trades. The stock’s average daily volume over the past 60 days is 754,846 and its 52-week low/high is $0.6171/$3.2929.

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) (“ABcann” or the “Company”) is pleased to announce that it has filed and obtained a receipt for a final short form prospectus (the “Prospectus”) in respect of its previously announced bought deal public offering (the “Offering”) of units and 6.0% unsecured convertible debentures of the Company.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

Abcann Global Corporation Announces Filing of Final Prospectus

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) Sees IIROC Trade Halt and Restart on the TSX-V

ABcann Completes Acquisition of Harvest Medicine

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0212, off by 11.67%, on 14,574,725 volume with 305 trades. The stock’s average daily volume over the past 60 days is 15,759,302, and its 52-week low/high is $0.0141/$0.16.

CannabisNewsAudio announces the Audio Press Release (APR) titled "The Modern Cannabis Industry — A Tight Mesh of Integrated Verticals and Technologies," featuring Global Payout, Inc. (GOHE). To hear the NetworkNewsAudio version, visit: http://nnw.fm/t5aF3. To read the original editorial, visit: http://nnw.fm/b9EdX.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

CannabisNewsAudio Announces Audio Press Release (APR) on Global Payout, Inc. Grasping Opportunity in Cannabis Industry's Interwoven Verticals

CannabisNewsWire Announces Publication on High-Potential Integrations Forming in Booming Cannabis Industry

Preparing for Growth: MoneyTrac Technology CEO Suspends Salary to Accelerate Expansion in 2018

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(CSRH) +120.00%

2.

StockMarketWatch
(ZSAN) +72.20%

3.

MarketBeat
(LKAI) +28.32%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251